Biocon

Nifty, Bank Nifty strategy; 3 stock recommendations by Motilal Oswal

Chandan Taparia of Motilal Oswal decodes how to trade Nifty and Bank Nifty today; here are stock bets and strategy

Claire has what it takes to lead Biocon forward: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson

Biocon eyes in-licensing opportunities to expand biosimilars portfolio

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

Biocon shares gain 3% despite 57% drop in Q4 profit; dividend announced

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Biocon Q4 result: Profit down 56.8% at ₹198.6 cr; revenue at ₹4,516.6 cr

Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at Rs 198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of Rs 80.4 crore on various heads, including impact of new labour code. The company had posted a consolidated net profit of Rs 459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday. Consolidated revenue from operations in the fourth quarter was at Rs 4,516.6 crore as against Rs 4,417 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 4,241.2 crore as compared to Rs 3,987.5 crore in the same period a year ago, it said. The company's board has recommended a final dividend of 50 paise per equity share of face value of Rs 5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said. For FY26, consolidated net profit was at Rs 368.8 crore, down from Rs 1,4

Q4 results today: Britannia, BSE, Biocon, Dabur India, 88 more on May 7

Q4FY26 company results: Firms including Lupin, Pidilite Industries, Bharat Forge, Escorts Kubota, and Indraprastha Gas are also to release their January-March earnings today

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon

Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase

Who is Claire Mazumdar, Kiran Mazumdar-Shaw's chosen successor for Biocon?

Claire Mazumdar, founding CEO of Bicara Therapeutics, has been named as successor to Biocon founder Kiran Mazumdar-Shaw, with a gradual leadership transition planned.

Biocon founder Kiran Mazumdar-Shaw picks niece Claire as successor

She plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to assume the chair in a phased manner

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

We've always been an India player, says Biocon MD Shreehas Tambe

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

Biocon appoints Shreehas Tambe as CEO & MD effective from April 1

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .

Kiran Mazumdar-Shaw sees AI-biology convergence transforming healthcare

Biocon Chairperson Kiran Mazumdar-Shaw on Friday said the convergence of biological intelligence and artificial intelligence (AI) can drive a paradigm shift in medicine, enabling breakthroughs in predictive healthcare, regenerative science and lifespan management. "Biology on its own was limited in generating deeper insights, but AI tools are opening immeasurable opportunities to understand living systems," Mazumdar-Shaw said while speaking at the AI Impact Summit here. She noted that biological systems function like distributed data centres, processing information with minimal energy compared to gigawatt-powered AI systems. "Biology has a lot to teach AI in terms of how to do it with less energy, how to do it rapidly, and how to multiplex multimodal data very quickly," she said. Mazumdar-Shaw described reprogramming cells - such as converting malignant cancer cells into non-malignant ones - as the 'holy grail' of medicine. She said AI could accelerate regenerative science and hel

Biopharma Shakti shows India focusing on being biopharma hub: Biocon's Shaw

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase

Stocks to Watch today: Coal India, SpiceJet, HUL, Biocon, Infosys, IRCTC

Stocks to watch today, Friday, February 13, 2026: Market participants will keep an eye on SpiceJet, Coal India, Biocon, Infosys, Mishra Dhatu Nigam, Indraprastha Gas share prices today

Biocon Q3FY26 results: Revenue up 9%, net profit rises on generics push

Board gives in-principle nod to make Biocon Biologics a wholly owned subsidiary as Q3 net profit climbs to Rs 143.8 crore

Stocks to Watch today, Jan 16: RIL, Infosys, ICICI Pru AMC, Jio Financial

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

Biocon raises ₹4,150 crore via QIP issue on strong investor demand

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon